PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer

被引：0

作者：

Xiangyu Qiu

Zhaoan Yu

Xiaoqing Lu

Xin Jin

Jinrong Zhu

Rongxin Zhang

机构：

[1] GuangdongProvincialKeyLaboratoryofAdvancedDrugDelivery,GuangdongProvincialEngineeringCenterofTopicalPreciseDrugDeliverySystem,SchoolofLifeSciencesandBiopharmaceutics,GuangdongPharmaceuticalUniversity

来源：

Cancer Biology & Medicine | 2024年 / 21卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

摘要：

<正>The emergence of tumor immunotherapy represents a pivotal milestone in cancer treatment, heralding new hope for cancer patients globally. Immune checkpoint inhibitors have been instrumental in this advance, playing a crucial role in modulating the immune system response to neoplasms. Specifically, the therapies targeting the programmed death 1/programmed cell death ligand 1（PD-1/PD-L1） immune checkpoint pathways have shown significant efficacy in treating various cancers1.

引用

页码：970 / 976

页数：7

共 50 条

[31] Targeting PD-1, TIM-3 and LAG-3 in combination for improved immunotherapy combinations
Kehry, Marilyn
Horlick, Robert
Bowers, Peter
Jun, Toni
Correia, Jean da Silva
Graves, Jonathan
Wang, Yan
Laken, Haley
King, David J.
CANCER RESEARCH, 2015, 75
[32] Assessment of the expression and response of PD-1, LAG-3, and TIM-3 after neoadjuvant radiotherapy in rectal cancer
Peng, Qing-Qin
Li, Jin-Luan
Xin, Pei-Ling
Du, Kai-Xin
Lin, Xiao-Yi
Wu, Jun-Xin
Zhang, Mu-Tian
Kong, Xiang-Quan
NEOPLASMA, 2021, 68 (04) : 742 - +
[33] Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade
Rivoltini, Licia
Camisaschi, Chiara
Fuca, Giovanni
Paolini, Biagio
Vergani, Barbara
Beretta, Valeria
Damian, Silvia
Duca, Matteo
Cresta, Sara
Magni, Michele
Leone, Biagio Eugenio
Castelli, Chiara
de Braud, Filippo
De Santis, Francesca
Di Nicola, Massimo
SCIENTIFIC REPORTS, 2024, 14 (01)
[34] Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade
Licia Rivoltini
Chiara Camisaschi
Giovanni Fucà
Biagio Paolini
Barbara Vergani
Valeria Beretta
Silvia Damian
Matteo Duca
Sara Cresta
Michele Magni
Biagio Eugenio Leone
Chiara Castelli
Filippo de Braud
Francesca De Santis
Massimo Di Nicola
Scientific Reports, 14
[35] Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
Huang, Ruea-Yea
Francois, Ariel
McGray, A. J. Robert
Miliotto, Anthony
Odunsi, Kunle
ONCOIMMUNOLOGY, 2017, 6 (01):
[36] Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection
Noah S Butler
Jacqueline Moebius
Lecia L Pewe
Boubacar Traore
Ogobara K Doumbo
Lorraine T Tygrett
Thomas J Waldschmidt
Peter D Crompton
John T Harty
Nature Immunology, 2012, 13 : 188 - 195
[37] Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection
Butler, Noah S.
Moebius, Jacqueline
Pewe, Lecia L.
Traore, Boubacar
Doumbo, Ogobara K.
Tygrett, Lorraine T.
Waldschmidt, Thomas J.
Crompton, Peter D.
Harty, John T.
NATURE IMMUNOLOGY, 2012, 13 (02) : 188 - 195
[38] Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy
Karapetyan, Lilit
Luke, Jason J.
CLINICAL CANCER RESEARCH, 2023, 29 (05) : 835 - 837
[39] Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL
Sunseri, Nicole
Chen, Xiufen
Wald, Noemie
Preillon, Julie
Smith, Sonali M.
Driessens, Gregory
Kline, Justin
BLOOD, 2019, 134
[40] Dual blockade of PD-L1 and LAG-3 using a bispecific antibody improves anti-tumor immunity
Ni, Haiqing
Qiu, Yajing
Jing, Hua
Zhang, Pan
Chen, Bingliang
Wu, Zhihai
Zhou, Shuaixiang
Yu, Michael
Liu, Junjian
CANCER RESEARCH, 2020, 80 (16)

← 1 2 3 4 5 →